Head and neck cancer incidence and two-year mortality in Aotearoa New Zealand, 2009-2020: a national population-based cohort study
In brief
Oropharyngeal cancer incidence climbed 44% in New Zealand over a decade
Among 6,980 people diagnosed with head and neck cancer from 2009 to 2020, oropharyngeal cancer incidence rose from 3.4 to 4.9 per 100,000 people, while oral cavity cancer rates were more stable. One in four patients died within two years, with higher early mortality among Maori, Pacific Peoples and people in the most deprived areas, underscoring persistent inequities.
- Journal
- Cancer epidemiology (Q1)
- Published
- 23 October 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Angad S Chauhan, Gabrielle Davie, David Barson, Sherly M Parackal, Takiwai Russell-Camp, Annie Wong
- PMID
- 42914788
- DOI
- 10.1016/j.canep.2026.103264
Why clinicians should know about it
- Picked for Epidemiology (paper of the day, 28 October 2026): National population-level cancer incidence and mortality inequalities
Abstract
BACKGROUND: Head and neck cancer (HNC) imposes a substantial burden in Aotearoa New Zealand (AoNZ), yet contemporary population-level data on incidence and early mortality across sociodemographic groups remain limited. METHODS: This population-based retrospective cohort study used New Zealand Cancer Registry to identify all primary HNC diagnoses from 2009 to 2020 (n = 6980). The cases were classified according to ICD-10 subsites. Incidence rates (IRs), age-standardised IRs, and age-standardised rate ratios were estimated by age, sex, ethnicity, socioeconomic deprivation, and rurality. Regression models were used to estimate annual percentage change in IRs and to estimate adjusted risk ratios for two-year all-cause mortality. RESULTS: In total 6980 people were diagnosed with HNC; an overall incidence rate of 13.5 per 100,000 person-years (PY). Oropharyngeal cancer (OPC), the most common subsite, increased from 3.4 per 100,000 PY in 2009-2011-4.9 per 100,000 PY in 2018-2020, whereas IRs for oral cavity cancer (OCC), the second most common, were more stable. HNC IRs were higher among males, older adults, Māori, Pacific Peoples and people living in the most socioeconomically deprived areas, with subsite-specific differences: Māori experienced higher OPC incidence rates, while Pacific Peoples experienced higher OCC IRs. Within two years of diagnosis, 25.2% of patients had died. Two-year all-cause mortality was 44.4% for hypopharyngeal cancer, 30.9% for OCC, and 22.7% for OPC. Among people diagnosed with HNC, after adjusting for available sociodemographic factors and treatment timing, two-year all-cause mortality was higher for Māori, Pacific Peoples, and those in the most deprived quintile. Rurality showed no consistent association with incidence or two-year mortality. CONCLUSIONS: These findings indicate an OPC-driven shift in HNC epidemiology in AoNZ and a persistent inequitable burden of both disease occurrence and early mortality, supporting stronger surveillance and equity-focused cancer-control responses.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.